Dose-proportional pharmacokinetics of terbinafine and its N-demethylated metabolite in healthy volunteers
- 1 February 1992
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 126 (s39) , 8-13
- https://doi.org/10.1111/j.1365-2133.1992.tb00002.x
Abstract
The dose-dependency of the pharmacokinetic parameters of terbinafine and its N-demethyl derivative was investigated in a randomized four-way crossover study in healthy volunteers following single oral administrations of 125, 250, 500 and 750 mg of terbinafine. Plasma concentrations of terbinafine and its metabolite were measured by a validated high-performance liquid chromatography (HPLC) method using ultraviolet detection. Concentration data were fitted to a two-compartment model. The relationship between Cmax or the area under the concentration curve (AUC) and the terbinafine dose was analysed by classical linear regression. Terbinafine disposition parameters were dose-independent, with the exception of Tmax and t1/2 alpha, which were prolonged with the 500- and 750-mg doses. The terbinafine Cmax and AUC, however, were linear and dose-proportional over the entire dose range. The N-demethylated metabolite appeared in plasma at the same time as terbinafine and showed similar prolongations in Tmax and t1/2 alpha with the 500- and 750-mg doses. In addition, the Cmax deviated from proportionality at these doses, giving values 22% lower than projected, while the AUC was linear and dose-proportional over the whole range of doses. The slight disproportionality in the dispositions of terbinafine and its N-demethyl metabolite at 500 and 750 mg are not expected to be clinically significant.Keywords
This publication has 13 references indexed in Scilit:
- Management of onychomycosis with oral terbinafineJournal of the American Academy of Dermatology, 1990
- Pharmacology of the allylaminesJournal of the American Academy of Dermatology, 1990
- Azoles and allylamines: the clinical implications of interaction with cytochrome P-450 enzymesJournal of Dermatological Treatment, 1990
- Clinical results with terbinafine in onychomycosisJournal of Dermatological Treatment, 1990
- A comparison of a new oral antifungal, terbinafine, with griseofulvin as therapy for tinea corporisArchives of Dermatology, 1989
- Clinical efficacy and tolerability of terbinafine (Lamisil)-a new topical and systemic fungicidal drug for treatment of dermatomycosesClinical and Experimental Dermatology, 1989
- Clinical pharmacokinetics of terbinafine (Lamisil)Clinical and Experimental Dermatology, 1989
- Antifungal activity of the allylamine derivative terbinafine in vitroAntimicrobial Agents and Chemotherapy, 1987
- Specific inhibition of fungal sterol biosynthesis by SF 86-327, a new allylamine antimycotic agentAntimicrobial Agents and Chemotherapy, 1985
- Allylamine Derivatives: New Class of Synthetic Antifungal Agents Inhibiting Fungal Squalene EpoxidaseScience, 1984